Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish kroner in European morning trading Wednesday, but remained down 25% since the start of the year. Roche shares traded 4.1% higher at 308.50 Swiss francs.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a standalone treatment and part of drug combinations for weight loss. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback